Top Markets
Coin of the day
Epigenomics AG Epigenomics AG

Epigenomics AG

ECX
Rang in aandelen #38933
Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a... Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG is a molecular diagnostics company dedicated to the early detection of cancer through liquid biopsy methods. Its primary offering, Epi proColon, is a blood-based assay specifically developed for the early identification of colorectal cancer, distributed across the United States, Europe, and China. The company's portfolio further encompasses a blood test for hepatocellular carcinoma and Epi BiSKit, a pre-analytical solution providing reagents essential for preparing bisulfite-converted DNA. Epigenomics' research and development initiatives are focused on pinpointing relevant biomarkers in human tissue and subsequently creating and securing patents for associated in vitro diagnostic blood tests.
Aandeelprijs
$0.83030862
Laatst gesynchroniseerd: 2024-06-27
Marktkapitalisatie
$726.64K
Verandering (1 dag)
-1.35%
Verandering (1 jaar)
0.00%
Land
DE
Handel Epigenomics AG (ECX)

Categorie

Dividendrendementgeschiedenis voor Epigenomics AG (ECX)
Het dividendrendement (TTM) van Epigenomics AG (aandelsymbool: ECX) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Epigenomics AG (ECX) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten